SenzaGen receives SEK 0.7m order for GARD®skin from one of the world’s largest pharmaceuticals companies
SenzaGen’s 2021 Half-Year Report: Positive ESAC opinion on GARD®skin and expanded range of tests open up new commercial opportunities
SenzaGens halvårsrapport 2021: Positivt ESAC-utlåtande om GARD®skin samt expanderat testutbud skapar nya kommersiella möjligheter